Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 53 resultados

VICT3R: Developing and implementing VIrtual Control groups To reducE animal use in toxicology Research VICT3R, a public-private partnership running under the European Innovative Health Initiative, aims to significantly reduce the number of ani...
2024-07-26 - 2028-02-29 | Financiado

EPND: European platform for neurodegenerative disorders UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Alzheimer’s disease (AD) and Parkinson’s disease (PD) are common neurodegenerative conditions, posing a major societal burden. There is a la...
2021-10-25 - 2026-10-31 | Financiado

SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado

HIPPOCRATES: Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging a...
2021-06-29 - 2026-06-30 | Financiado

BIGPICTURE: Central Repository for Digital Pathology UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

PharmaLedger: PharmaLedger UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the...
2019-12-16 - 2022-12-31 | Financiado

INSPIRE: INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse... UCB BIOPHARMA participó en un H2020: H2020-MSCA-ITN-2019 New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pha...
2019-08-19 - 2024-05-31 | Financiado

ConcePTION: Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and... UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about...
2019-05-06 - 2024-12-31 | Financiado

NeuroDeRisk: Neurotoxicity De Risking in Preclinical Drug Discovery UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage The adverse effects of pharmaceuticals on the central or peripheral nervous systems are poorly predicted by the current in vitro and in vivo...
2019-03-15 - 2022-09-30 | Financiado

EBiSC2: EBiSC2 A sustainable European Bank for induced pluripotent Stem Cells UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique bank...
2019-02-28 - 2023-02-28 | Financiado

BIOMAP: Biomarkers in Atopic Dermatitis and Psoriasis UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molec...
2019-02-27 - 2025-03-31 | Financiado

PD-MitoQUANT: PD MitoQUANT A quantitative approach towards the characterisation of mitochondrial dysfunction in... UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-13-two-stage Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is...
2019-02-19 - 2022-07-31 | Financiado

ESCulab: European Screening Centre Unique Library for Attractive Biology UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific...
2018-12-18 - 2023-11-30 | Financiado

EHDEN: European Health Data and Evidence Network UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage Europe is generating huge amounts of patient-level information contained in Electronic Health Record (EHR) systems and other types of health...
2018-11-22 - 2024-10-31 | Financiado

CODOBIO: Continuous Downstream Processing of Bioproducts UCB BIOPHARMA participó en un H2020: H2020-MSCA-ITN-2018 Continuous biomanufacturing is one of the grand challenges of Europe’s bio-industry. It offers a significant opportunity to boost productivi...
2018-08-30 - 2023-08-31 | Financiado

GetReal Initiative: The GetReal Initiative UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practice...
2018-06-26 - 2021-04-30 | Financiado

AIMS-2-TRIALS: Autism Innovative Medicine Studies 2 Trials UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental condition affecting over five million people in the European Union. Th...
2018-06-22 - 2025-05-31 | Financiado

c4c: conect4children COllaborative Network for European Clinical Trials For Children UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado

EFOEUPATI: Ensuring the future of EUPATI beyond 2020 UCB BIOPHARMA participó en un H2020: H2020-JTI-IMI2-2017-11-single-stage The European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient e...
2018-06-21 - 2020-09-30 | Financiado